These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 7850956)

  • 1. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody.
    Biemond BJ; Levi M; Coronel R; Janse MJ; ten Cate JW; Pannekoek H
    Circulation; 1995 Feb; 91(4):1175-81. PubMed ID: 7850956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arterial diastolic pressure augmentation by intra-aortic balloon counterpulsation enhances the onset of coronary artery reperfusion by thrombolytic therapy.
    Gurbel PA; Anderson RD; MacCord CS; Scott H; Komjathy SF; Poulton J; Stafford JL; Godard J
    Circulation; 1994 Jan; 89(1):361-5. PubMed ID: 8281671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
    Przyklenk K; Kloner RA
    Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits.
    Friederich PW; Levi M; Biemond BJ; Charlton P; Templeton D; van Zonneveld AJ; Bevan P; Pannekoek H; ten Cate JW
    Circulation; 1997 Aug; 96(3):916-21. PubMed ID: 9264501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody.
    Yasuda T; Gold HK; Leinbach RC; Saito T; Guerrero JL; Jang IK; Holt R; Fallon JT; Collen D
    J Am Coll Cardiol; 1990 Dec; 16(7):1728-35. PubMed ID: 2123910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation.
    Gold HK; Coller BS; Yasuda T; Saito T; Fallon JT; Guerrero JL; Leinbach RC; Ziskind AA; Collen D
    Circulation; 1988 Mar; 77(3):670-7. PubMed ID: 3124974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjunctive therapy with low molecular weight heparin with recombinant tissue-type plasminogen activator causes sustained reflow in canine coronary thrombosis.
    Nicolini FA; Nichols WW; Saldeen TG; Khan S; Mehta JL
    Am Heart J; 1992 Aug; 124(2):280-8. PubMed ID: 1322029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cilostazol, a novel cyclic AMP phosphodiesterase inhibitor, prevents reocclusion after coronary arterial thrombolysis with recombinant tissue-type plasminogen activator.
    Saitoh S; Saito T; Otake A; Owada T; Mitsugi M; Hashimoto H; Maruyama Y
    Arterioscler Thromb; 1993 Apr; 13(4):563-70. PubMed ID: 8385480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis.
    Levi M; Biemond BJ; van Zonneveld AJ; ten Cate JW; Pannekoek H
    Circulation; 1992 Jan; 85(1):305-12. PubMed ID: 1728462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
    Nicolini FA; Nichols WW; Saldeen TG; Mehta JL
    Cardiovasc Res; 1991 Apr; 25(4):283-9. PubMed ID: 1909212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
    Sitko GR; Ramjit DR; Stabilito II; Lehman D; Lynch JJ; Vlasuk GP
    Circulation; 1992 Feb; 85(2):805-15. PubMed ID: 1735171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of reocclusion following tissue type plasminogen activator-induced thrombolysis by the RGD-containing peptide, echistatin, in a canine model of coronary thrombosis.
    Holahan MA; Mellott MJ; Garsky VM; Shebuski RJ
    Pharmacology; 1991; 42(6):340-8. PubMed ID: 1946598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation.
    Yasuda T; Gold HK; Leinbach RC; Yaoita H; Fallon JT; Guerrero L; Napier MA; Bunting S; Collen D
    Circulation; 1991 Mar; 83(3):1038-47. PubMed ID: 1900221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of arterial reocclusion after thrombolysis with activated protein C. Comparison with heparin in a canine model of coronary artery thrombosis.
    Sakamoto T; Ogawa H; Yasue H; Oda Y; Kitajima S; Tsumoto K; Mizokami H
    Circulation; 1994 Jul; 90(1):427-32. PubMed ID: 8026029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs.
    Yasuda T; Gold HK; Fallon JT; Leinbach RC; Guerrero JL; Scudder LE; Kanke M; Shealy D; Ross MJ; Collen D; Coller BS
    J Clin Invest; 1988 Apr; 81(4):1284-91. PubMed ID: 2832448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
    Yao SK; Ober JC; Ferguson JJ; Anderson HV; Maraganore J; Buja LM; Willerson JT
    Circulation; 1992 Dec; 86(6):1993-9. PubMed ID: 1451271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis.
    Nicolini FA; Lee P; Rios G; Kottke-Marchant K; Topol EJ
    Circulation; 1994 Apr; 89(4):1802-9. PubMed ID: 8149546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does external ultrasound accelerate thrombolysis? Results from a rabbit model.
    Kornowski R; Meltzer RS; Chernine A; Vered Z; Battler A
    Circulation; 1994 Jan; 89(1):339-44. PubMed ID: 8281667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostacyclin analogue iloprost decreases thrombolytic potential of tissue-type plasminogen activator in canine coronary thrombosis.
    Nicolini FA; Mehta JL; Nichols WW; Saldeen TG; Grant M
    Circulation; 1990 Mar; 81(3):1115-22. PubMed ID: 1689620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibody against tissue factor shortens tissue plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombosis.
    Ragni M; Cirillo P; Pascucci I; Scognamiglio A; D'Andrea D; Eramo N; Ezekowitz MD; Pawashe AB; Chiariello M; Golino P
    Circulation; 1996 May; 93(10):1913-8. PubMed ID: 8635271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.